Patients
Clinical Trials
Our clinical trials help to advance the understanding of innovative medicines and determine whether the new treatments being developed are safe and effective.
We know that the decision to participate in clinical trial research is not made lightly, and we sincerely thank all the patients and families who choose to partake. Your physician is the best person to help you decide if a clinical trial or any other treatment option is right for you.
The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.
Vepdegestrant is an investigational orally bioavailable PROTAC® protein degrader designed to target and degrade the estrogen receptor (ER) for the treatment of patients with locally advanced or metastatic ER-positive / HER2-negative breast cancer.
Vepdegestrant is an investigational compound. It’s safety and efficacy has not been established.
Currently Recruiting:
- ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer (NCT05501769)
- A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (NCT04072952)
- A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery (NCT05549505)
- A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2) (NCT05654623)
- TACTIVE-U: A Study to Learn About the Study Medicine (Called ARV-471) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) (NCT05548127)
- TACTIVE-U: A Study to Learn About the Study Medicine (Called ARV-471) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) (NCT05573555)
If you’re interested in learning more about this trial, please speak with your doctor and visit the website www.clinicaltrials.gov
Collaborator:
Currently Recruiting:
- Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (NCT05177042)
- Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (NCT03888612)
If you’re interested in learning more about this trial, please speak with your doctor and visit the website www.clinicaltrials.gov
ARV-766 is an investigational orally bioavailable PROTAC® protein degrader designed to selectively target and degrade the androgen receptor (AR). ARV-766 is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer (mCRPC).
Currently Recruiting:
- Clinical Trial to Evaluate ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT05067140)
If you’re interested in learning more about this trial, please speak with your doctor and visit the website www.clinicaltrials.gov
